View ValuationRocket Doctor AI 향후 성장Future 기준 점검 2/6Rocket Doctor AI의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Healthcare Services 이익 성장20.3%매출 성장률47.9%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트12 Jun 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 29Rocket Doctor AI Inc. announced that it expects to receive CAD 2 million in fundingRocket Doctor AI Inc. to announce a non-brokered private placement of unsecured convertible debentures in the amount of CAD 1,000 each in the aggregate principal amount of up to CAD 2,000,000 on July 28, 2026. The Debentures will bear interest from the date of issuance at a rate of 12.0% per annum, calculated and payable on maturity which is 12 months following the issuance of the Debentures. The principal amount of the Debentures, together with any accrued and unpaid interest, may be converted, in whole or in part at the election of the holder, into units of the Company at a conversion price of CAD 0.70 per Unit on the earlier of: (i) the business day immediately preceding the Maturity Date; and (ii) the business day immediately preceding the date fixed for redemption of the Debentures by the Company, if any, subject to the terms therein. Each Unit will consist of one common share in the capital of the Company and one transferable Share purchase warrant (a “Warrant”), with each Warrant being exercisable into one Share (a “Warrant Share”) at an exercise price of CAD 0.75 per Warrant Share for a period of 12 months from the date of issuance pursuant to the terms therein. The Warrant Expiry Date may be accelerated in the event the Shares trade on the CSE at CAD 0.75 or more per Common Share for any 10 consecutive trading days, and, upon delivery of a notice to the holder, the Warrant Expiry Date will be accelerated to 5:00pm on the date that is 10 calendar days from the date of delivery of an acceleration notice to the holder. Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including that of the CSE. The securities issued in connection with the Offering will be subject to applicable statutory hold periods imposed under applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions and may close in one or more tranches. The Company anticipates paying finders' fees to eligible parties who have assisted in introducing subscribers to the Offering. Any finders' fees payable will be in accordance with the policies of the CSE.공고 • Jul 07Rocket Doctor Ai Inc. Announces CFO ChangesRocket Doctor AI Inc. had appointed Mr. Andrew Lau, CPA, CA as Chief Financial Officer, effective July 6, 2026. Mr. Lau brought over 18 years of capital markets, corporate finance, and public company experience to Rocket Doctor AI. Throughout his career, he had held executive finance leadership roles with high-growth technology and life sciences companies, where he had led corporate finance, treasury, financial reporting, corporate development, and public company initiatives. Mr. Lau began his career with Deloitte LLP, where he earned his Chartered Professional Accountant designation, before joining RBC Capital Markets as an investment banker specializing in M&A and equity financing transactions. Over the course of his career, he had advised on and executed more than $700 million in M&A and capital markets transactions and had played a key role in helping emerging growth companies scale, strengthen their financial operations, and access the public markets. Mr. Lau replaced Mr. Chris Cherry, who stepped down as Interim CFO to return to his role as Chair of the Audit Committee while continuing his service as a director.공고 • Jun 17Treatment.Com Inc Receives Year 2 Funding from National Institute on Minority Health and Health DisparitiesRocket Doctor AI Inc. announced that Treatment.com Inc., in collaboration with Rush River Research, had received confirmation of second-year funding from the National Institute on Minority Health and Health Disparities, part of the National Institutes of Health. The funding granted follows the successful completion of the program’s first-year milestones and extends support for the development of an AI-powered family medical history tool designed to make preventive care more accurate, accessible, and culturally responsive. The second-year award provides Treatment with in excess of USD 250,000 in additional support, with the program agreement now extended through May 31, 2027. This extension provides Treatment with over USD 500,000 to enhance its Global Library of Medicine and AI-powered clinical tools. The two-year project is supported by a highly competitive Small Business Innovation Research grant with a total award value of approximately USD 2 million. As part of the Year 2 extension, Treatment will receive more than USD 250,000 in additional funding, bringing its total program support to more than USD 500,000. The project agreement now extends through May 31, 2027.공고 • Jan 23Rocket Doctor AI Inc. announced that it has received CAD 5.2 million in fundingOn January 22, 2026,Rocket Doctor AI Inc. closed the transaction. In connection with the closing of the transaction, the company paid to certain finders cash commission of CAD 198,800 and issued 284,000 non-transferrable warrants of the Company exercisable at any time until January 22, 2027 to acquire one Common Share at an exercise price of CAD 0.85, subject to adjustment in certain events. The securities issued in the Offering are not subject to a hold period in accordance with applicable Canadian securities laws.공고 • Dec 09Rocket Doctor AI, Health Cities and CAN Health Network Partner to Advance AI-Powered Clinical Decision Support in AlbertaRocket Doctor AI Inc. announced a new partnership with the CAN Health Network to test its AI-powered Clinical Decision Support System (CDSS) in collaboration with Health Cities. The project will launch at up to four primary care sites in Alberta to help physicians deliver faster, evidence-based, and more efficient care. The program was developed in accordance with Health Cities' need for an integrated, AI-powered solution capable of analyzing diverse data sources, automating routine tasks, and delivering real-time clinical recommendations. The project, running from November 2025 to March 2026, involves approximately 20 clinicians and aims to set the foundation for a potential full provincial rollout in 2026. As a CAN Health Network Primary Care Edge, Health Cities creates an environment where innovative solutions can be co-developed, validated, and adopted to address real-world health challenges. The initiative rolls out in three phases, beginning with AI-powered patient intake through a website-embedded chatbot, followed by real-time clinician support during visits, and ultimately integration with electronic medical records (EMRs). Rocket Doctor AI's Global Library of Medicine (GLM) is a clinically-validated decision engine developed with input from hundreds of physicians to assist providers with triage, differential diagnosis, and evidence-based care planning. This project comes at a critical time for Alberta's healthcare system, where staffing shortages, limited access to primary care, and increasing patient loads continue to strain clinics across the province. Recent data shows that one in five Albertans lacks a family physician, with many communities facing long wait times for basic care. This project aims to directly address these challenges by supporting clinicians with intelligent, AI-driven tools that improve efficiency and patient access. Key anticipated outcomes include a 25-40% reduction in physician intake time, as well as improved patient satisfaction through faster and clearer communication. The CDSS is also expected to significantly reduce physicians' administrative workload, including less time on charting, documentation, and billing. Rocket Doctor AI's platform will be hosted in secure, Canadian-based data centres, aligned with HIPAA, PIPEDA, and Alberta's Health Information Act (HIA). The modular system architecture ensures future growth, with the capability to scale across Alberta's 4,400 providers and beyond. This project is made possible through funding and support from the CAN Health Network, a federally funded initiative designed to help Canadian companies scale innovative healthcare solutions domestically. The partnership underscores Rocket Doctor AI's commitment to advancing equitable access to care, supporting overburdened clinicians, and modernizing healthcare delivery through responsible AI innovation. A Commercialization Project Agreement was entered into by the parties on 12th November 2025. The Agreement details the intent of the parties to collaborate in jointly delivering a Commercialization Project. Either party may propose amendments or terminate this Agreement upon written notice.공고 • Dec 06Rocket Doctor AI Inc. Announces Change of Chief Financial Officer, Effective December 8, 2025Rocket Doctor AI Inc. announced that Christopher Cherry shall assume the role of Interim Chief Financial Officer, to replace David Worner, effective December 8, 2025. Mr. Cherry is currently the Company’s Chair of the Audit Committee.공고 • Sep 10Rocket Doctor AI Inc., Annual General Meeting, Oct 22, 2025Rocket Doctor AI Inc., Annual General Meeting, Oct 22, 2025.공고 • Sep 04Rocket Doctor Is Now In-Network for Aetna in New York State for Medicare and Commercial Health InsuranceRocket Doctor AI Inc. announced that doctors using its wholly-owned digital health platform and marketplace, Rocket Doctor Inc., are now in-network with Aetna in New York State, having been fully credentialed for Medicare and commercial plans. This milestone expands Rocket Doctor's ability to provide in-network care to Aetna members throughout the state. By combining urgent care, primary care and mental health, alongside connected medical devices and proprietary software, Rocket Doctor delivers high-quality care virtually that is both affordable and accessible, especially for patients on Medicaid and Medicare, and in rural and underserved communities. Rocket Doctor's programs include urgent care, chronic disease management, preventive health and mental health services, enabling patients to see licensed physicians from home. With in-network status, Aetna members in New York can access these services with lower out-of-pocket costs and greater convenience. Rocket Doctor is also active in New York through its partnership with EngageWell IPA and the CVS Health Foundation, which launched the Healthy Aging Program earlier this year. The pilot initiative provides free, virtual health screenings for adults over 60 in New York City, including assessments for heart health, cognitive function and mental health, along with personalized follow-up support from community health workers. The program, backed by $1 million in CVS Health Foundation funding, is designed to help older adults age with confidence, care and convenience. Rocket Doctor AI continues to expand its payer and health system partnerships across North America. The Options are each exercisable for one common share of the Company at an exercise price of CAD 0.67 per share for a period of three years from the grant date and vest over a one-year term. The RSUs are valid for a term of three years and vest over a one- year. The Options and RSUs are subject to the terms of the Company's equity plans and applicable securities law hold periods.공고 • Aug 22Rocket Doctor AI Inc. announced that it has received CAD 4.2347 million in fundingOn August 21, 2025, Rocket Doctor AI Inc. closed the oversubscribed transaction. The company issued 3,677,400 special warrants at an issue price of CAD 0.50 per special warrant for gross proceeds of CAD 1,838,700 and 4,792,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 2,396,000 for aggregate gross proceeds of CAD 4,234,700. Each unit is comprised of one common share of the company and one share purchase warrant of the company, with each warrant exercisable into one share at an exercise price of CAD 0.75 for 12 months from the date of issuance of the warrants. Each special warrant will automatically convert, for no additional consideration, into one unit. No special warrants may be exercised by the holder thereof prior to the conversion date. In connection with the offering, the company has paid finder’s fees totaling CAD 201,616 and issued an aggregate of 403,232 non-transferable broker warrants to arm’s-length parties. Each broker warrant entitles the holder to purchase one share at an exercise price of CAD 0.75 per share for a period of 12 months from the date of issuance of the broker warrants. The special warrants and the securities issuable upon conversion of the special warrants are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The units issued and the broker warrants, including the securities issuable thereunder, are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation.공고 • Jul 26Treatment.com AI Inc. announced that it expects to receive CAD 3 million in fundingTreatment.com AI Inc. has announced a non-brokered private placement to issue special warrants of the company at a price of CAD 0.50 per warrant and Units of the company at a price of CAD 0.5 per Unit for gross proceeds of up to CAD 3 million on July 25, 2025. Each unit shall consist of one common share and one common share purchase warrant. Each warrant shall entitle the holder thereof to acquire one Share at a price of CAD 0.75 per Share for a period of 12 months following the date of issuance of the warrants. The Special warrants will be convertible into Units of the company. The Company may pay a finder’s fee of up to 8% of the gross proceeds of the offering and may issue to certain eligible finders non-transferable broker warrants equal up to 8% of the number of special warrants and/or units sold under the offering. Each Broker Warrant will entitle the holder to purchase one Share at a price of CAD 0.75 per Broker Share for a period of 12 months from the date of issuance. The transaction is expected to close on August 18, 2025. All the securities issued under the offering is subject to a lock up period of four months and one day from the date of issuance.공고 • Jun 11Treatment.com AI Inc. Announces New Medical Education Suite to Enhance Clinical Skills Training Through AI-Simulated PatientsTreatment.com AI Inc. announced that it has released its latest version of the Medical Education Suite (MES). The University of Minnesota Medical School has successfully completed a live deployment of Treatment.com AI's new Medical Education Suite (MES), an AI-powered clinical skills assessment platform designed to support medical schools in delivering scalable, rigorous, and cost-effective Objective Structured Clinical Examinations (OSCEs). The deployment, conducted with over 240 third-year medical students, marked the first large-scale implementation of computer-simulated patient cases developed through the Global Library of Medicine (GLM), a clinician-built medical knowledge engine. The exams ran with complete technical reliability during deployment, as well as integrating seamlessly into the school's existing OSCE workflow. The MES is a scalable platform designed to reduce administrative and faculty time, improve objectivity, increase evaluation consistency, and provide a robust digital infrastructure to support both live and AI-simulated formats. The focus of the platform is to help enhance the clinical skills of next generation of healthcare professionals. By incorporating curated AI-generated cases and the supportive services provided by Treatment, the system enables: Significant reduction in faculty preparation and administrative workload. Real-time scoring that aligns directly with clinical learning objectives. Objective student evaluations with built-in educational and remediation support. Alignment with LCME standards. Secure and scalable exam delivery on campus or remotely. The University of Minnesota has calculated their Administrative cost savings ~ 40%. The MES combines AI-simulated patients with automated feedback, helping faculty assess diagnostic and management reasoning, clinical prioritization, and documentation quality, all mapped to learning objectives. Early feedback suggests that the platform enhances the student learning experience and strengthens the reliability of OSCE results. Preliminary results of the accuracy and precision of the GLM as applied in the MES platform were presented at the AAMC's 2025 Group on Information Resources meeting. Prof. Violato, Dr. Peterson, and their respective teams are preparing further scientific publications detailing the methodology, deployment, and outcomes of the UMN program. Treatment.com AI is engaging with a wide variety of other schools, with the goal to extend the MES offering across North America, the UK, and to other international OSCE markets.공고 • Apr 10Treatment.com AI Inc. (CNSX:TRUE) completed the acquisition of 100% shares in Rocket Doctor Inc.Treatment.com AI Inc. (CNSX:TRUE) entered into a definitive agreement to acquire 100% shares in Rocket Doctor Inc. for CAD 21.5 million on February 11, 2025. As part of consideration, Treatment.com would pay Rocket Doctor Inc (i) common shares of Treatment.com with a fair market value of $7,688,640 (CAD 11,008,749) payable on closing of the Proposed Transaction and (ii) subject to the achievement of certain 12 and 24 month milestones, additional common shares of Treatment with a fair market value of up to $6,902,560 (CAD 9,883,223) payable to the holders of SAFEs and shareholders of Rocket Doctor. In connection with the Proposed Transaction, by virtue of acquiring Rocket Doctor, Treatment.com AI Inc. will be assuming approximately CAD 627,000 in long term liabilities of Rocket Doctor. The Transaction is subject to a number of conditions, including the receipt of regulatory approvals and approval of the CSE. Treatment.com AI Inc. (CNSX:TRUE) completed the acquisition of 100% shares in Rocket Doctor Inc. on April 10, 2025.공고 • Mar 14Treatment.com AI Inc. announced that it has received CAD 3.3 million in fundingOn March 13, 2025, Treatment.com AI Inc. closed the transaction.공고 • Feb 28Treatment.com AI Inc. announced that it expects to receive CAD 3 million in fundingTreatment.com AI Inc. announced that it has entered into an agreement with Ventum Financial Corp.as underwriter and sole bookrunner in connection with a brokered private placement of 6,000,000 units at a price of CAD 0.50 per Unit for gross proceeds to the Company of CAD 3,000,000 on February 27, 2025. Each Unit will consist of one common share and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder thereof to purchase one Common Share of the Company for a period of 24 months following the Closing Date at an exercise price of CAD 0.75 per Warrant Share. . The Units issued pursuant to the Offering will not be subject to a hold period in accordance with applicable Canadian securities laws. Upon closing of the Offering, the Company will pay to the Underwriter a cash fee equal to 8.0% of the aggregate gross proceeds of the Offering and issue to the Underwriter warrants exercisable at any time prior to the date that is 24 months from the Closing Date to acquire that number of Units equal to 8.0% of the number of Units issued under the Offering, at an exercise price equal to the Offering Price, subject to adjustment in certain events. The Offering may close in tranches. The Offering is expected to close on or before March 12, 2025. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange.공고 • Feb 13Treatment.com AI Inc. (CNSX:TRUE) entered into a definitive agreement to acquire Rocket Doctor Inc. for CAD 20.89 million.Treatment.com AI Inc. (CNSX:TRUE) entered into a definitive agreement to acquire Rocket Doctor Inc. for CAD 20.89 million on February 12, 2025. As part of consideration, Treatment.com would pay Rocket Doctor Inc (i) common shares of Treatment.com with a fair market value of CAD 11.008749 ($7,688,640) payable on closing of the Proposed Transaction and (ii) subject to the achievement of certain 12 and 24 month milestones, additional common shares of Treatment with a fair market value of up to CAD 9.883223 ($6,902,560) payable to the holders of SAFEs and shareholders of Rocket Doctor. In connection with the Proposed Transaction, by virtue of acquiring Rocket Doctor, Treatment.com AI Inc. will be assuming approximately $542,000 in long term liabilities of Rocket Doctor. The Transaction is subject to a number of conditions, including the receipt of regulatory approvals and approval of the CSE.공고 • Nov 05Treatment.com AI Inc. Announces Launch of its Updated Medical Education SuiteTreatment.com AI Inc. announced the launch of its updated Medical Education Suite (MES) to coincide with Treatment’s participation in a landmark Symposium on AI Assessment in Medical Education being hosted by the University of Minnesota Medical School on 1st November 2024. It is estimated that over 80 countries globally have now adopted the OSCE (Objective Structured Clinical Examination) for assessing the practical clinical skills of medical students. It is estimated that between 200,000 and 300,000 medical students globally take the OSCE exam each year, as derived from indicative numbers of students from key professional bodies including: https://www.aamc.org/; https://www.uems.eu/; https://www.nmc.org.in/; Education – GMC (gmc-uk.org). As announced in a previous 2024 Press Releases,Treatment has been working diligently through 2024 to further evolve the Medical Education Suite (MES), powered by its proprietary Global Library of Medicine (GLM). The goal of furthering enhancements to the platform is the recognition that AI can be used even more effectively to reduce the administrative overhead and costs to schools in running OSCEs, as well providing greater support to medical students, thereby helping to optimize their clinical reasoning skills. Treatment’s service comprises of using its Global Library of Medicine platform (GLM) in (i) creating cases for the OSCE exams (ii) producing scripts for actors playing the role of patients (iii) scoring the exams with its proprietary automated marking platform and (iv) providing instant results to both faculty and students, as well as offering student enrichment plans. As part of this Release, Treatment is announcing the following additions to its portfolio: AI Patient – utilizing AI and a library of test Cases to further support students in their preparation and readiness for medical multiple-choice questions (MCQ’s) and OSCE exams. Objective Structured Clinical Examination (OSCE) Case Packages – the company is extending the number of test Cases provided from an initial 12 cases. These will be available in packs to schools and a planned library of up to 100 cases through fourth quarter 2024. AI Prep Tool – the platform provides students with both a “guided” and “non-guided” support to learning. The “guided” approach provides students with learning support and reasoning, whereas the “non-guided” supports enables students to simulate exam conditions. Together with the launch of its updated Medical Education Suite, Treatment is a lead participant in a Symposium on AI Assessment in Medical Education held on November 1, 2024 at the University of Minnesota Medical School, Office of Assessment and Evaluation. The creator of the Symposium, Dr. Claudio Violato described the event as a “landmark symposium”. This academic Symposium includes more than fifty medical schools, thought leaders and national education examiners from across the US, as well as international representation. Presenters include Mayo Clinic, University of Alberta as well as Treatment’s Chief Medical Officer Kevin Peterson, MD, MPH, who will be a keynote speaker, as an acknowledged leader in medical education and its utilization of AI. Treatment will continue to build out its Medical Education Suite through the rest of 2024 and early 2025. Further planned developments include: AI Doctor in a Pocket – delivers a mobile friendly AI powered clinical decision support tool for healthcare professionals and students when they are in clinics, residency or on a hospital ward. Audio/Video Analysis – using AI and the Global Library of Medicine to undertake Audio/Visual analysis which captures and transcribes the patient assessment. In addition, this will allow for behavioral analysis as part of exam scoring, as well as supporting the generation of a medical note.공고 • Jul 31Treatment.com AI Announces AI Pharmacy AssistantTreatment.com AI Inc. announced a new solution, AI Pharmacy Assistant designed to support pharmacists. Pharmacists are playing an increasing role in the provision of clinical decision support services, given the increasing number of people without a GP and/or the time taken to book appointments. This is representative of similar trends being seen across Canada, UK and emerging legislation in the US, all of which will lead to extending the role for pharmacists within the healthcare continuum of care. Globally, pharmacists will play a significant role in alleviating the shortages of healthcare professionals, timeliness of patient support and mitigating the financial pressures prevalent in today's healthcare systems. For many people, especially in underserved communities, the pharmacist is often the only healthcare professional people see. Therefore, providing these pharmacists with the tools and confidence to administer a wider range of services, has a positive impact for them and the wellbeing of their communities. Working with pharmacists, Treatment is excited to be announcing its new AI Pharmacy Assistant solution for pharmacists, expected to launch later in 2024. The solution is underpinned by Treatment's AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library. The GLM has been created with hundreds of credentialled clinicians globally to ensure the highest qualified clinical information and support to all healthcare professionals. AI Pharmacy Assistant will be either accessible on a patient's mobile device or through a kiosk tablet at the pharmacy. It will support pharmacists in multiple ways: Reducing the time to take patient histories and symptoms using Treatment's GLM; Automatically document all interactions with patients providing an audit trail; Extending confidence and support in expanded diagnostic support provided to patients; Minimize the risk of errors and increase clinical efficiency; Providing comprehensive diagnostic and symptom information backed by the most reliable and up-to-date medical research. The global clinical decision support systems (CDSS) market is projected to grow significantly, reaching approximately $4.05 billion by 2029 from $2.46 billion in 2024, driven by technological advancements and the integration of AI and machine learning in healthcare decision-making processes. Whilst there is a clear desire to expand the pharmacist's scope of practice, there is also a huge shortage of pharmacists globally. Therefore, pharmacists are being stretched at both ends: more work, less staff. Supportive and accurate support tools which can be trusted, such as Treatment's AI Pharmacy Assistant, will be a pivotal part of the solution.공고 • May 09Treatment.com AI Inc. Announces Appointment of Richard Atkins as Chief Operating Officer and Executive Team MemberTreatment.com AI Inc. announced the appointment of Richard Atkins as Chief Operating Officer and a member of the executive team. Mr. Atkins brings to the business a successful career with over 30 years’ experience in international sales, partnerships, executive management and M&A, highlighted by multiple multi-million dollar deals working with both major health-tech and software corporations. Mr. Atkins spent his formative career in software and technology including: networking, managed services, data centers & virtualization, omnichannel contact centers, CRM, enterprise search/data analytics, cloud-based applications. However, for the past 15 years, he has brought his experience to healthcare, working across the continuum of care, with a focus on clinical decision support. His experience spans innovative international physical and mental health solutions including: Digital Health - healthbots, symptom checkers, telehealth, Alexa voice and social media solutions, National/Provincial teletriage services, Managed PACS/RIS and LIM services in both public/private sectors, EMR/Billing and HL7/FHIR interoperability. His experience includes multi-million dollar contracts with the NHS (England and Scotland); national/regional triage services in Australia, Europe and North America; building out formative triage services in Africa through to working with US based Health Navigator (acquired by Amazon Care in 2019).공고 • May 08Treatment.com AI Inc., Annual General Meeting, Jul 08, 2024Treatment.com AI Inc., Annual General Meeting, Jul 08, 2024.공고 • Apr 17Treatment.com AI Inc. Announces New Additions to Its Medical Education Suite (MES)Treatment.com AI Inc. announced two new solutions, (1) AI Patient and (2) AI Doctor in a Pocket, to augment its Medical Education Suite ("MES") designed to educate the next generation of healthcare providers. Treatment's MES enhances the entire continuum of clinical content education, from simple introductory patient interactions to more advanced USMLE diagnostic evaluations and grading to complex faculty benchmarking. It is designed to reduce faculty administration costs and time, provide a comprehensive range of clinical experiences, and offer students a digital self-test companion to enhance their understanding of diagnostic clinical approaches. The suite of solutions provides support for faculty and students in both design and preparation for the OSCE (Objective Structured Clinical examination). This established clinical exam is used in 57 countries to test the practical reasoning of healthcare professional students and measure their progress in clinical diagnosis and treatment. The market in the US alone comprises 300 medical schools; 900 nursing schools;227,000 students and 145,000 residents/medical students. Treatment is also in discussions with schools in the UK and Canada. Treatment is excited to be announcing two new monthly subscription-based SaaS solutions for students, residents and all healthcare professionals expected to launch in the second half of 2024: AI Patient - utilizing AI and a library of test cases to further support students in their preparation and readiness for medical multiple-choice questions (MCQ's) and OSCE exams; AIDoctor in a Pocket - delivers a mobile friendly AI powered clinical decision support tool for healthcare professionals and students when they are in clinics or on a ward. Both solutions are underpinned by Treatment's AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library. The GLM has been created with hundreds of credentialled clinicians globally to ensure the highest qualified clinical information and support to all healthcare professionals.공고 • Mar 15Treatment.com AI Inc. announced that it has received CAD 2.9082 million in fundingOn March 14, 2024, Treatment.com AI Inc. closed the transaction. The company issued 6,295,500 special warrants at a price of CAD 0.40 per special warrant for gross proceeds of CAD 2,518,200; and 975,000 units at a price of CAD 0.40 per unit for gross proceeds of CAD 390,000; for aggregate gross proceeds of CAD 2,908,200 in the transaction. Each unit is comprised of one common share and one-half of one share purchase warrant, with each warrant exercisable into one additional share at an exercise price of CAD 0.60 for two years from the date of closing. The company has paid finder’s fees totaling CAD 220,816 and issued an aggregate 552,040 non-transferable broker warrants to arm’s-length parties. Each broker warrant entitles the holder to purchase one common share at an exercise price of CAD 0.60 per broker share for a period of two years from the date of closing.공고 • Feb 18Treatment.com AI Inc. announced that it expects to receive CAD 2 million in fundingTreatment.com AI Inc. announced a non-brokered private placement to issue up to 5,000,000 special warrants at a price of CAD 0.4 per warrant for the gross proceeds of up to CAD 2,000,000 on February 16, 2024. Each Special Warrant will automatically convert without payment of any additional consideration into one unit of the company on the date that is the earlier of the third business day after a) a receipt for a final prospectus; the date of filing a prospectus supplement to a short form base shelf prospectus qualifying the distribution of the Shares and Warrants issuable upon the conversion of the Special Warrants and 4 months and one day after the issue date of the Special Warrants. Each Unit will be comprised of one common share of the Company and one-half of one share purchase warrant of the Company, with each Warrant exercisable into one additional share at an exercise price of CAD 0.60 for 2 years from the date of closing. The Company may pay a finder's fee of up to 8% of the gross proceeds of the Offering and may issue to certain eligible finders non-transferable broker warrants equal up to 8% of the number of Special Warrants sold under the offering. The Offering is expected to close on or before February 29, 2024. The offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions.공고 • Oct 19+ 1 more updateTreatment.Com International Inc. Appoints Dr. Essam Hamza, MD as Chief Executive OfficerTreatment.com International Inc. announced the appointment of Dr. Essam Hamza, MD as Chief Executive Officer, effective October 17, 2023. Dr.Hamza will also join the Board on that date. The appointment of Dr. Hamza follows a mandate to appoint a leader with a rare combination of extensive healthcare, technology and capital markets experience capable of leading the Company through the next phase of its growth. Dr.Hamza is a proven executer with a track record of successfully founding, leading and growing transformational healthcare companies. Most recently, he was the founder, a Director and CEO of CloudMD, a Vancouver based healthcare technology company. Dr. Hamza is a seasoned and highly successful business visionary, steeped in medical and healthcare experience through his over 20 years as a medical doctor and a business builder as the founder of several healthcare companies including CloudMD Inc. From 2019 to 2022 at CloudMD, Dr. Hamza lead the company through tremendous growth, from a handful of employees and approximately $4M in annual sales in Canada, to hundreds of employees and customers across North American and over $100 million in annual sales. Dr.Hamza is a proven leader and has a track record of success delivered through his extradonirary ability and understanding of healthcare, technology and entrepreneurship.공고 • Oct 06Treatment.Com International Inc. announced that it has received CAD 0.37125 million in fundingOn October 5, 2023, Treatment.Com International Inc. closed the transaction. The company amended the terms of the transaction and issued 2,475,000 common shares in the capital of the company at a price of CAD 0.15 per common share, for aggregate gross proceeds of up to CAD 371,250.공고 • Oct 01Treatment.Com International Inc. announced that it has received CAD 1 million in fundingOn September 29, 2023, Treatment.Com International Inc. closed the transaction. The company paid finder's fee in cash of CAD 17,500 and 175,000 non-transferable share purchase warrants. Each finder's warrant entitles the holder thereof to acquire one common share at a price of CAD 0.255 per common share until September 29, 2025.공고 • Sep 29Treatment.Com International Inc. announced that it expects to receive CAD 0.5 million in fundingTreatment.Com International Inc. announced a non-brokered private placement of up to 3,333,333 common shares in the capital of the company at a price of CAD 0.15 per common share, for aggregate gross proceeds of up to CAD 500,000 on September 29, 2023. The offering is expected to close on or before October 10, 2023. The offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The offering is not subject to a minimum aggregate amount of subscriptions.공고 • Aug 18Treatment.Com International Inc. announced that it expects to receive CAD 1 million in fundingTreatment.Com International Inc. announced a private placement of 10,000,000 common shares at a price of CAD 0.10 per share for the gross proceeds of CAD 1 million on August 18, 2023. Closing of the transaction is subject to the Canadian Securities Exchange approval and shareholder's approval pursuant to the policies of the Canadian Securities Exchange. No finder's fees is payable in connection with the transaction.공고 • May 19Treatment.Com International Inc. Announces CEO ChangesTreatment.com International Inc. announced the resignation of Dr. Paul A. Markham as Chief Executive Officer of the Company. Mr. Kevin Peterson, Chair of the Board, shall assume the role as Interim Chief Executive Officer.이익 및 매출 성장 예측OTCPK:AIRD.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CAD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20276,069N/AN/A-7,278112/31/20264,159N/AN/A-9,011112/31/20251,614N/AN/A-5,39119/30/20230-200N/A6/30/2023N/A-200N/A3/31/2023N/A-2-1-1N/A12/31/2022N/A-4-1-1N/A9/30/2022N/A-9-2-2N/A6/30/2022N/A-13-5-5N/A3/31/2022N/A-15-6-6N/A12/31/2021N/A-14-6-6N/A9/30/2021N/A-9-6-6N/A6/30/2021N/A-5-4-4N/A3/31/2021N/A-4-3-3N/A12/31/2020N/A-3-2-2N/A9/30/2020N/A-4-2-2N/A12/31/2019N/A-3-1-1N/A12/31/2018N/A000N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: AIRD.F 의 예상 수익 증가율이 절약률(3.7%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: AIRD.F 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: AIRD.F 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: AIRD.F 의 수익(연간 47.9%)이 US 시장(연간 12.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: AIRD.F 의 수익(연간 47.9%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: AIRD.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/21 05:33종가2026/08/21 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Rocket Doctor AI Inc.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Siddharth RajeevFundamental Research Corp.
공고 • Jul 29Rocket Doctor AI Inc. announced that it expects to receive CAD 2 million in fundingRocket Doctor AI Inc. to announce a non-brokered private placement of unsecured convertible debentures in the amount of CAD 1,000 each in the aggregate principal amount of up to CAD 2,000,000 on July 28, 2026. The Debentures will bear interest from the date of issuance at a rate of 12.0% per annum, calculated and payable on maturity which is 12 months following the issuance of the Debentures. The principal amount of the Debentures, together with any accrued and unpaid interest, may be converted, in whole or in part at the election of the holder, into units of the Company at a conversion price of CAD 0.70 per Unit on the earlier of: (i) the business day immediately preceding the Maturity Date; and (ii) the business day immediately preceding the date fixed for redemption of the Debentures by the Company, if any, subject to the terms therein. Each Unit will consist of one common share in the capital of the Company and one transferable Share purchase warrant (a “Warrant”), with each Warrant being exercisable into one Share (a “Warrant Share”) at an exercise price of CAD 0.75 per Warrant Share for a period of 12 months from the date of issuance pursuant to the terms therein. The Warrant Expiry Date may be accelerated in the event the Shares trade on the CSE at CAD 0.75 or more per Common Share for any 10 consecutive trading days, and, upon delivery of a notice to the holder, the Warrant Expiry Date will be accelerated to 5:00pm on the date that is 10 calendar days from the date of delivery of an acceleration notice to the holder. Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including that of the CSE. The securities issued in connection with the Offering will be subject to applicable statutory hold periods imposed under applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions and may close in one or more tranches. The Company anticipates paying finders' fees to eligible parties who have assisted in introducing subscribers to the Offering. Any finders' fees payable will be in accordance with the policies of the CSE.
공고 • Jul 07Rocket Doctor Ai Inc. Announces CFO ChangesRocket Doctor AI Inc. had appointed Mr. Andrew Lau, CPA, CA as Chief Financial Officer, effective July 6, 2026. Mr. Lau brought over 18 years of capital markets, corporate finance, and public company experience to Rocket Doctor AI. Throughout his career, he had held executive finance leadership roles with high-growth technology and life sciences companies, where he had led corporate finance, treasury, financial reporting, corporate development, and public company initiatives. Mr. Lau began his career with Deloitte LLP, where he earned his Chartered Professional Accountant designation, before joining RBC Capital Markets as an investment banker specializing in M&A and equity financing transactions. Over the course of his career, he had advised on and executed more than $700 million in M&A and capital markets transactions and had played a key role in helping emerging growth companies scale, strengthen their financial operations, and access the public markets. Mr. Lau replaced Mr. Chris Cherry, who stepped down as Interim CFO to return to his role as Chair of the Audit Committee while continuing his service as a director.
공고 • Jun 17Treatment.Com Inc Receives Year 2 Funding from National Institute on Minority Health and Health DisparitiesRocket Doctor AI Inc. announced that Treatment.com Inc., in collaboration with Rush River Research, had received confirmation of second-year funding from the National Institute on Minority Health and Health Disparities, part of the National Institutes of Health. The funding granted follows the successful completion of the program’s first-year milestones and extends support for the development of an AI-powered family medical history tool designed to make preventive care more accurate, accessible, and culturally responsive. The second-year award provides Treatment with in excess of USD 250,000 in additional support, with the program agreement now extended through May 31, 2027. This extension provides Treatment with over USD 500,000 to enhance its Global Library of Medicine and AI-powered clinical tools. The two-year project is supported by a highly competitive Small Business Innovation Research grant with a total award value of approximately USD 2 million. As part of the Year 2 extension, Treatment will receive more than USD 250,000 in additional funding, bringing its total program support to more than USD 500,000. The project agreement now extends through May 31, 2027.
공고 • Jan 23Rocket Doctor AI Inc. announced that it has received CAD 5.2 million in fundingOn January 22, 2026,Rocket Doctor AI Inc. closed the transaction. In connection with the closing of the transaction, the company paid to certain finders cash commission of CAD 198,800 and issued 284,000 non-transferrable warrants of the Company exercisable at any time until January 22, 2027 to acquire one Common Share at an exercise price of CAD 0.85, subject to adjustment in certain events. The securities issued in the Offering are not subject to a hold period in accordance with applicable Canadian securities laws.
공고 • Dec 09Rocket Doctor AI, Health Cities and CAN Health Network Partner to Advance AI-Powered Clinical Decision Support in AlbertaRocket Doctor AI Inc. announced a new partnership with the CAN Health Network to test its AI-powered Clinical Decision Support System (CDSS) in collaboration with Health Cities. The project will launch at up to four primary care sites in Alberta to help physicians deliver faster, evidence-based, and more efficient care. The program was developed in accordance with Health Cities' need for an integrated, AI-powered solution capable of analyzing diverse data sources, automating routine tasks, and delivering real-time clinical recommendations. The project, running from November 2025 to March 2026, involves approximately 20 clinicians and aims to set the foundation for a potential full provincial rollout in 2026. As a CAN Health Network Primary Care Edge, Health Cities creates an environment where innovative solutions can be co-developed, validated, and adopted to address real-world health challenges. The initiative rolls out in three phases, beginning with AI-powered patient intake through a website-embedded chatbot, followed by real-time clinician support during visits, and ultimately integration with electronic medical records (EMRs). Rocket Doctor AI's Global Library of Medicine (GLM) is a clinically-validated decision engine developed with input from hundreds of physicians to assist providers with triage, differential diagnosis, and evidence-based care planning. This project comes at a critical time for Alberta's healthcare system, where staffing shortages, limited access to primary care, and increasing patient loads continue to strain clinics across the province. Recent data shows that one in five Albertans lacks a family physician, with many communities facing long wait times for basic care. This project aims to directly address these challenges by supporting clinicians with intelligent, AI-driven tools that improve efficiency and patient access. Key anticipated outcomes include a 25-40% reduction in physician intake time, as well as improved patient satisfaction through faster and clearer communication. The CDSS is also expected to significantly reduce physicians' administrative workload, including less time on charting, documentation, and billing. Rocket Doctor AI's platform will be hosted in secure, Canadian-based data centres, aligned with HIPAA, PIPEDA, and Alberta's Health Information Act (HIA). The modular system architecture ensures future growth, with the capability to scale across Alberta's 4,400 providers and beyond. This project is made possible through funding and support from the CAN Health Network, a federally funded initiative designed to help Canadian companies scale innovative healthcare solutions domestically. The partnership underscores Rocket Doctor AI's commitment to advancing equitable access to care, supporting overburdened clinicians, and modernizing healthcare delivery through responsible AI innovation. A Commercialization Project Agreement was entered into by the parties on 12th November 2025. The Agreement details the intent of the parties to collaborate in jointly delivering a Commercialization Project. Either party may propose amendments or terminate this Agreement upon written notice.
공고 • Dec 06Rocket Doctor AI Inc. Announces Change of Chief Financial Officer, Effective December 8, 2025Rocket Doctor AI Inc. announced that Christopher Cherry shall assume the role of Interim Chief Financial Officer, to replace David Worner, effective December 8, 2025. Mr. Cherry is currently the Company’s Chair of the Audit Committee.
공고 • Sep 10Rocket Doctor AI Inc., Annual General Meeting, Oct 22, 2025Rocket Doctor AI Inc., Annual General Meeting, Oct 22, 2025.
공고 • Sep 04Rocket Doctor Is Now In-Network for Aetna in New York State for Medicare and Commercial Health InsuranceRocket Doctor AI Inc. announced that doctors using its wholly-owned digital health platform and marketplace, Rocket Doctor Inc., are now in-network with Aetna in New York State, having been fully credentialed for Medicare and commercial plans. This milestone expands Rocket Doctor's ability to provide in-network care to Aetna members throughout the state. By combining urgent care, primary care and mental health, alongside connected medical devices and proprietary software, Rocket Doctor delivers high-quality care virtually that is both affordable and accessible, especially for patients on Medicaid and Medicare, and in rural and underserved communities. Rocket Doctor's programs include urgent care, chronic disease management, preventive health and mental health services, enabling patients to see licensed physicians from home. With in-network status, Aetna members in New York can access these services with lower out-of-pocket costs and greater convenience. Rocket Doctor is also active in New York through its partnership with EngageWell IPA and the CVS Health Foundation, which launched the Healthy Aging Program earlier this year. The pilot initiative provides free, virtual health screenings for adults over 60 in New York City, including assessments for heart health, cognitive function and mental health, along with personalized follow-up support from community health workers. The program, backed by $1 million in CVS Health Foundation funding, is designed to help older adults age with confidence, care and convenience. Rocket Doctor AI continues to expand its payer and health system partnerships across North America. The Options are each exercisable for one common share of the Company at an exercise price of CAD 0.67 per share for a period of three years from the grant date and vest over a one-year term. The RSUs are valid for a term of three years and vest over a one- year. The Options and RSUs are subject to the terms of the Company's equity plans and applicable securities law hold periods.
공고 • Aug 22Rocket Doctor AI Inc. announced that it has received CAD 4.2347 million in fundingOn August 21, 2025, Rocket Doctor AI Inc. closed the oversubscribed transaction. The company issued 3,677,400 special warrants at an issue price of CAD 0.50 per special warrant for gross proceeds of CAD 1,838,700 and 4,792,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 2,396,000 for aggregate gross proceeds of CAD 4,234,700. Each unit is comprised of one common share of the company and one share purchase warrant of the company, with each warrant exercisable into one share at an exercise price of CAD 0.75 for 12 months from the date of issuance of the warrants. Each special warrant will automatically convert, for no additional consideration, into one unit. No special warrants may be exercised by the holder thereof prior to the conversion date. In connection with the offering, the company has paid finder’s fees totaling CAD 201,616 and issued an aggregate of 403,232 non-transferable broker warrants to arm’s-length parties. Each broker warrant entitles the holder to purchase one share at an exercise price of CAD 0.75 per share for a period of 12 months from the date of issuance of the broker warrants. The special warrants and the securities issuable upon conversion of the special warrants are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The units issued and the broker warrants, including the securities issuable thereunder, are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation.
공고 • Jul 26Treatment.com AI Inc. announced that it expects to receive CAD 3 million in fundingTreatment.com AI Inc. has announced a non-brokered private placement to issue special warrants of the company at a price of CAD 0.50 per warrant and Units of the company at a price of CAD 0.5 per Unit for gross proceeds of up to CAD 3 million on July 25, 2025. Each unit shall consist of one common share and one common share purchase warrant. Each warrant shall entitle the holder thereof to acquire one Share at a price of CAD 0.75 per Share for a period of 12 months following the date of issuance of the warrants. The Special warrants will be convertible into Units of the company. The Company may pay a finder’s fee of up to 8% of the gross proceeds of the offering and may issue to certain eligible finders non-transferable broker warrants equal up to 8% of the number of special warrants and/or units sold under the offering. Each Broker Warrant will entitle the holder to purchase one Share at a price of CAD 0.75 per Broker Share for a period of 12 months from the date of issuance. The transaction is expected to close on August 18, 2025. All the securities issued under the offering is subject to a lock up period of four months and one day from the date of issuance.
공고 • Jun 11Treatment.com AI Inc. Announces New Medical Education Suite to Enhance Clinical Skills Training Through AI-Simulated PatientsTreatment.com AI Inc. announced that it has released its latest version of the Medical Education Suite (MES). The University of Minnesota Medical School has successfully completed a live deployment of Treatment.com AI's new Medical Education Suite (MES), an AI-powered clinical skills assessment platform designed to support medical schools in delivering scalable, rigorous, and cost-effective Objective Structured Clinical Examinations (OSCEs). The deployment, conducted with over 240 third-year medical students, marked the first large-scale implementation of computer-simulated patient cases developed through the Global Library of Medicine (GLM), a clinician-built medical knowledge engine. The exams ran with complete technical reliability during deployment, as well as integrating seamlessly into the school's existing OSCE workflow. The MES is a scalable platform designed to reduce administrative and faculty time, improve objectivity, increase evaluation consistency, and provide a robust digital infrastructure to support both live and AI-simulated formats. The focus of the platform is to help enhance the clinical skills of next generation of healthcare professionals. By incorporating curated AI-generated cases and the supportive services provided by Treatment, the system enables: Significant reduction in faculty preparation and administrative workload. Real-time scoring that aligns directly with clinical learning objectives. Objective student evaluations with built-in educational and remediation support. Alignment with LCME standards. Secure and scalable exam delivery on campus or remotely. The University of Minnesota has calculated their Administrative cost savings ~ 40%. The MES combines AI-simulated patients with automated feedback, helping faculty assess diagnostic and management reasoning, clinical prioritization, and documentation quality, all mapped to learning objectives. Early feedback suggests that the platform enhances the student learning experience and strengthens the reliability of OSCE results. Preliminary results of the accuracy and precision of the GLM as applied in the MES platform were presented at the AAMC's 2025 Group on Information Resources meeting. Prof. Violato, Dr. Peterson, and their respective teams are preparing further scientific publications detailing the methodology, deployment, and outcomes of the UMN program. Treatment.com AI is engaging with a wide variety of other schools, with the goal to extend the MES offering across North America, the UK, and to other international OSCE markets.
공고 • Apr 10Treatment.com AI Inc. (CNSX:TRUE) completed the acquisition of 100% shares in Rocket Doctor Inc.Treatment.com AI Inc. (CNSX:TRUE) entered into a definitive agreement to acquire 100% shares in Rocket Doctor Inc. for CAD 21.5 million on February 11, 2025. As part of consideration, Treatment.com would pay Rocket Doctor Inc (i) common shares of Treatment.com with a fair market value of $7,688,640 (CAD 11,008,749) payable on closing of the Proposed Transaction and (ii) subject to the achievement of certain 12 and 24 month milestones, additional common shares of Treatment with a fair market value of up to $6,902,560 (CAD 9,883,223) payable to the holders of SAFEs and shareholders of Rocket Doctor. In connection with the Proposed Transaction, by virtue of acquiring Rocket Doctor, Treatment.com AI Inc. will be assuming approximately CAD 627,000 in long term liabilities of Rocket Doctor. The Transaction is subject to a number of conditions, including the receipt of regulatory approvals and approval of the CSE. Treatment.com AI Inc. (CNSX:TRUE) completed the acquisition of 100% shares in Rocket Doctor Inc. on April 10, 2025.
공고 • Mar 14Treatment.com AI Inc. announced that it has received CAD 3.3 million in fundingOn March 13, 2025, Treatment.com AI Inc. closed the transaction.
공고 • Feb 28Treatment.com AI Inc. announced that it expects to receive CAD 3 million in fundingTreatment.com AI Inc. announced that it has entered into an agreement with Ventum Financial Corp.as underwriter and sole bookrunner in connection with a brokered private placement of 6,000,000 units at a price of CAD 0.50 per Unit for gross proceeds to the Company of CAD 3,000,000 on February 27, 2025. Each Unit will consist of one common share and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder thereof to purchase one Common Share of the Company for a period of 24 months following the Closing Date at an exercise price of CAD 0.75 per Warrant Share. . The Units issued pursuant to the Offering will not be subject to a hold period in accordance with applicable Canadian securities laws. Upon closing of the Offering, the Company will pay to the Underwriter a cash fee equal to 8.0% of the aggregate gross proceeds of the Offering and issue to the Underwriter warrants exercisable at any time prior to the date that is 24 months from the Closing Date to acquire that number of Units equal to 8.0% of the number of Units issued under the Offering, at an exercise price equal to the Offering Price, subject to adjustment in certain events. The Offering may close in tranches. The Offering is expected to close on or before March 12, 2025. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange.
공고 • Feb 13Treatment.com AI Inc. (CNSX:TRUE) entered into a definitive agreement to acquire Rocket Doctor Inc. for CAD 20.89 million.Treatment.com AI Inc. (CNSX:TRUE) entered into a definitive agreement to acquire Rocket Doctor Inc. for CAD 20.89 million on February 12, 2025. As part of consideration, Treatment.com would pay Rocket Doctor Inc (i) common shares of Treatment.com with a fair market value of CAD 11.008749 ($7,688,640) payable on closing of the Proposed Transaction and (ii) subject to the achievement of certain 12 and 24 month milestones, additional common shares of Treatment with a fair market value of up to CAD 9.883223 ($6,902,560) payable to the holders of SAFEs and shareholders of Rocket Doctor. In connection with the Proposed Transaction, by virtue of acquiring Rocket Doctor, Treatment.com AI Inc. will be assuming approximately $542,000 in long term liabilities of Rocket Doctor. The Transaction is subject to a number of conditions, including the receipt of regulatory approvals and approval of the CSE.
공고 • Nov 05Treatment.com AI Inc. Announces Launch of its Updated Medical Education SuiteTreatment.com AI Inc. announced the launch of its updated Medical Education Suite (MES) to coincide with Treatment’s participation in a landmark Symposium on AI Assessment in Medical Education being hosted by the University of Minnesota Medical School on 1st November 2024. It is estimated that over 80 countries globally have now adopted the OSCE (Objective Structured Clinical Examination) for assessing the practical clinical skills of medical students. It is estimated that between 200,000 and 300,000 medical students globally take the OSCE exam each year, as derived from indicative numbers of students from key professional bodies including: https://www.aamc.org/; https://www.uems.eu/; https://www.nmc.org.in/; Education – GMC (gmc-uk.org). As announced in a previous 2024 Press Releases,Treatment has been working diligently through 2024 to further evolve the Medical Education Suite (MES), powered by its proprietary Global Library of Medicine (GLM). The goal of furthering enhancements to the platform is the recognition that AI can be used even more effectively to reduce the administrative overhead and costs to schools in running OSCEs, as well providing greater support to medical students, thereby helping to optimize their clinical reasoning skills. Treatment’s service comprises of using its Global Library of Medicine platform (GLM) in (i) creating cases for the OSCE exams (ii) producing scripts for actors playing the role of patients (iii) scoring the exams with its proprietary automated marking platform and (iv) providing instant results to both faculty and students, as well as offering student enrichment plans. As part of this Release, Treatment is announcing the following additions to its portfolio: AI Patient – utilizing AI and a library of test Cases to further support students in their preparation and readiness for medical multiple-choice questions (MCQ’s) and OSCE exams. Objective Structured Clinical Examination (OSCE) Case Packages – the company is extending the number of test Cases provided from an initial 12 cases. These will be available in packs to schools and a planned library of up to 100 cases through fourth quarter 2024. AI Prep Tool – the platform provides students with both a “guided” and “non-guided” support to learning. The “guided” approach provides students with learning support and reasoning, whereas the “non-guided” supports enables students to simulate exam conditions. Together with the launch of its updated Medical Education Suite, Treatment is a lead participant in a Symposium on AI Assessment in Medical Education held on November 1, 2024 at the University of Minnesota Medical School, Office of Assessment and Evaluation. The creator of the Symposium, Dr. Claudio Violato described the event as a “landmark symposium”. This academic Symposium includes more than fifty medical schools, thought leaders and national education examiners from across the US, as well as international representation. Presenters include Mayo Clinic, University of Alberta as well as Treatment’s Chief Medical Officer Kevin Peterson, MD, MPH, who will be a keynote speaker, as an acknowledged leader in medical education and its utilization of AI. Treatment will continue to build out its Medical Education Suite through the rest of 2024 and early 2025. Further planned developments include: AI Doctor in a Pocket – delivers a mobile friendly AI powered clinical decision support tool for healthcare professionals and students when they are in clinics, residency or on a hospital ward. Audio/Video Analysis – using AI and the Global Library of Medicine to undertake Audio/Visual analysis which captures and transcribes the patient assessment. In addition, this will allow for behavioral analysis as part of exam scoring, as well as supporting the generation of a medical note.
공고 • Jul 31Treatment.com AI Announces AI Pharmacy AssistantTreatment.com AI Inc. announced a new solution, AI Pharmacy Assistant designed to support pharmacists. Pharmacists are playing an increasing role in the provision of clinical decision support services, given the increasing number of people without a GP and/or the time taken to book appointments. This is representative of similar trends being seen across Canada, UK and emerging legislation in the US, all of which will lead to extending the role for pharmacists within the healthcare continuum of care. Globally, pharmacists will play a significant role in alleviating the shortages of healthcare professionals, timeliness of patient support and mitigating the financial pressures prevalent in today's healthcare systems. For many people, especially in underserved communities, the pharmacist is often the only healthcare professional people see. Therefore, providing these pharmacists with the tools and confidence to administer a wider range of services, has a positive impact for them and the wellbeing of their communities. Working with pharmacists, Treatment is excited to be announcing its new AI Pharmacy Assistant solution for pharmacists, expected to launch later in 2024. The solution is underpinned by Treatment's AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library. The GLM has been created with hundreds of credentialled clinicians globally to ensure the highest qualified clinical information and support to all healthcare professionals. AI Pharmacy Assistant will be either accessible on a patient's mobile device or through a kiosk tablet at the pharmacy. It will support pharmacists in multiple ways: Reducing the time to take patient histories and symptoms using Treatment's GLM; Automatically document all interactions with patients providing an audit trail; Extending confidence and support in expanded diagnostic support provided to patients; Minimize the risk of errors and increase clinical efficiency; Providing comprehensive diagnostic and symptom information backed by the most reliable and up-to-date medical research. The global clinical decision support systems (CDSS) market is projected to grow significantly, reaching approximately $4.05 billion by 2029 from $2.46 billion in 2024, driven by technological advancements and the integration of AI and machine learning in healthcare decision-making processes. Whilst there is a clear desire to expand the pharmacist's scope of practice, there is also a huge shortage of pharmacists globally. Therefore, pharmacists are being stretched at both ends: more work, less staff. Supportive and accurate support tools which can be trusted, such as Treatment's AI Pharmacy Assistant, will be a pivotal part of the solution.
공고 • May 09Treatment.com AI Inc. Announces Appointment of Richard Atkins as Chief Operating Officer and Executive Team MemberTreatment.com AI Inc. announced the appointment of Richard Atkins as Chief Operating Officer and a member of the executive team. Mr. Atkins brings to the business a successful career with over 30 years’ experience in international sales, partnerships, executive management and M&A, highlighted by multiple multi-million dollar deals working with both major health-tech and software corporations. Mr. Atkins spent his formative career in software and technology including: networking, managed services, data centers & virtualization, omnichannel contact centers, CRM, enterprise search/data analytics, cloud-based applications. However, for the past 15 years, he has brought his experience to healthcare, working across the continuum of care, with a focus on clinical decision support. His experience spans innovative international physical and mental health solutions including: Digital Health - healthbots, symptom checkers, telehealth, Alexa voice and social media solutions, National/Provincial teletriage services, Managed PACS/RIS and LIM services in both public/private sectors, EMR/Billing and HL7/FHIR interoperability. His experience includes multi-million dollar contracts with the NHS (England and Scotland); national/regional triage services in Australia, Europe and North America; building out formative triage services in Africa through to working with US based Health Navigator (acquired by Amazon Care in 2019).
공고 • May 08Treatment.com AI Inc., Annual General Meeting, Jul 08, 2024Treatment.com AI Inc., Annual General Meeting, Jul 08, 2024.
공고 • Apr 17Treatment.com AI Inc. Announces New Additions to Its Medical Education Suite (MES)Treatment.com AI Inc. announced two new solutions, (1) AI Patient and (2) AI Doctor in a Pocket, to augment its Medical Education Suite ("MES") designed to educate the next generation of healthcare providers. Treatment's MES enhances the entire continuum of clinical content education, from simple introductory patient interactions to more advanced USMLE diagnostic evaluations and grading to complex faculty benchmarking. It is designed to reduce faculty administration costs and time, provide a comprehensive range of clinical experiences, and offer students a digital self-test companion to enhance their understanding of diagnostic clinical approaches. The suite of solutions provides support for faculty and students in both design and preparation for the OSCE (Objective Structured Clinical examination). This established clinical exam is used in 57 countries to test the practical reasoning of healthcare professional students and measure their progress in clinical diagnosis and treatment. The market in the US alone comprises 300 medical schools; 900 nursing schools;227,000 students and 145,000 residents/medical students. Treatment is also in discussions with schools in the UK and Canada. Treatment is excited to be announcing two new monthly subscription-based SaaS solutions for students, residents and all healthcare professionals expected to launch in the second half of 2024: AI Patient - utilizing AI and a library of test cases to further support students in their preparation and readiness for medical multiple-choice questions (MCQ's) and OSCE exams; AIDoctor in a Pocket - delivers a mobile friendly AI powered clinical decision support tool for healthcare professionals and students when they are in clinics or on a ward. Both solutions are underpinned by Treatment's AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library. The GLM has been created with hundreds of credentialled clinicians globally to ensure the highest qualified clinical information and support to all healthcare professionals.
공고 • Mar 15Treatment.com AI Inc. announced that it has received CAD 2.9082 million in fundingOn March 14, 2024, Treatment.com AI Inc. closed the transaction. The company issued 6,295,500 special warrants at a price of CAD 0.40 per special warrant for gross proceeds of CAD 2,518,200; and 975,000 units at a price of CAD 0.40 per unit for gross proceeds of CAD 390,000; for aggregate gross proceeds of CAD 2,908,200 in the transaction. Each unit is comprised of one common share and one-half of one share purchase warrant, with each warrant exercisable into one additional share at an exercise price of CAD 0.60 for two years from the date of closing. The company has paid finder’s fees totaling CAD 220,816 and issued an aggregate 552,040 non-transferable broker warrants to arm’s-length parties. Each broker warrant entitles the holder to purchase one common share at an exercise price of CAD 0.60 per broker share for a period of two years from the date of closing.
공고 • Feb 18Treatment.com AI Inc. announced that it expects to receive CAD 2 million in fundingTreatment.com AI Inc. announced a non-brokered private placement to issue up to 5,000,000 special warrants at a price of CAD 0.4 per warrant for the gross proceeds of up to CAD 2,000,000 on February 16, 2024. Each Special Warrant will automatically convert without payment of any additional consideration into one unit of the company on the date that is the earlier of the third business day after a) a receipt for a final prospectus; the date of filing a prospectus supplement to a short form base shelf prospectus qualifying the distribution of the Shares and Warrants issuable upon the conversion of the Special Warrants and 4 months and one day after the issue date of the Special Warrants. Each Unit will be comprised of one common share of the Company and one-half of one share purchase warrant of the Company, with each Warrant exercisable into one additional share at an exercise price of CAD 0.60 for 2 years from the date of closing. The Company may pay a finder's fee of up to 8% of the gross proceeds of the Offering and may issue to certain eligible finders non-transferable broker warrants equal up to 8% of the number of Special Warrants sold under the offering. The Offering is expected to close on or before February 29, 2024. The offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions.
공고 • Oct 19+ 1 more updateTreatment.Com International Inc. Appoints Dr. Essam Hamza, MD as Chief Executive OfficerTreatment.com International Inc. announced the appointment of Dr. Essam Hamza, MD as Chief Executive Officer, effective October 17, 2023. Dr.Hamza will also join the Board on that date. The appointment of Dr. Hamza follows a mandate to appoint a leader with a rare combination of extensive healthcare, technology and capital markets experience capable of leading the Company through the next phase of its growth. Dr.Hamza is a proven executer with a track record of successfully founding, leading and growing transformational healthcare companies. Most recently, he was the founder, a Director and CEO of CloudMD, a Vancouver based healthcare technology company. Dr. Hamza is a seasoned and highly successful business visionary, steeped in medical and healthcare experience through his over 20 years as a medical doctor and a business builder as the founder of several healthcare companies including CloudMD Inc. From 2019 to 2022 at CloudMD, Dr. Hamza lead the company through tremendous growth, from a handful of employees and approximately $4M in annual sales in Canada, to hundreds of employees and customers across North American and over $100 million in annual sales. Dr.Hamza is a proven leader and has a track record of success delivered through his extradonirary ability and understanding of healthcare, technology and entrepreneurship.
공고 • Oct 06Treatment.Com International Inc. announced that it has received CAD 0.37125 million in fundingOn October 5, 2023, Treatment.Com International Inc. closed the transaction. The company amended the terms of the transaction and issued 2,475,000 common shares in the capital of the company at a price of CAD 0.15 per common share, for aggregate gross proceeds of up to CAD 371,250.
공고 • Oct 01Treatment.Com International Inc. announced that it has received CAD 1 million in fundingOn September 29, 2023, Treatment.Com International Inc. closed the transaction. The company paid finder's fee in cash of CAD 17,500 and 175,000 non-transferable share purchase warrants. Each finder's warrant entitles the holder thereof to acquire one common share at a price of CAD 0.255 per common share until September 29, 2025.
공고 • Sep 29Treatment.Com International Inc. announced that it expects to receive CAD 0.5 million in fundingTreatment.Com International Inc. announced a non-brokered private placement of up to 3,333,333 common shares in the capital of the company at a price of CAD 0.15 per common share, for aggregate gross proceeds of up to CAD 500,000 on September 29, 2023. The offering is expected to close on or before October 10, 2023. The offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The offering is not subject to a minimum aggregate amount of subscriptions.
공고 • Aug 18Treatment.Com International Inc. announced that it expects to receive CAD 1 million in fundingTreatment.Com International Inc. announced a private placement of 10,000,000 common shares at a price of CAD 0.10 per share for the gross proceeds of CAD 1 million on August 18, 2023. Closing of the transaction is subject to the Canadian Securities Exchange approval and shareholder's approval pursuant to the policies of the Canadian Securities Exchange. No finder's fees is payable in connection with the transaction.
공고 • May 19Treatment.Com International Inc. Announces CEO ChangesTreatment.com International Inc. announced the resignation of Dr. Paul A. Markham as Chief Executive Officer of the Company. Mr. Kevin Peterson, Chair of the Board, shall assume the role as Interim Chief Executive Officer.